Abstract
ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index. The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type. In patients with nonmuscle invasive bladder urothelial carcinoma th...Continue Reading
References
Jan 1, 1990·European Urology·B LlopisJ F Jiménez-Cruz
Oct 1, 1987·The Journal of Urology·E Orihuela, R S Shahon
Jul 1, 1980·The Journal of Urology·A J NewmanS Johnson
Jan 1, 1993·Scandinavian Journal of Urology and Nephrology·M P Raitanen, T L Tammela
Mar 20, 1998·International Journal of Cancer. Journal International Du Cancer·I OrlowC Cordón-Cardó
Jun 24, 1999·The Journal of Urology·H W Herr
Dec 2, 1999·Biochimica Et Biophysica Acta·S Hakomori
Aug 1, 2002·Proceedings of the National Academy of Sciences of the United States of America·Senitiroh Hakomori
Jan 30, 2004·International Journal of Cancer. Journal International Du Cancer·Shan GaoErik Dabelsteen
May 10, 2005·Laboratory Investigation; a Journal of Technical Methods and Pathology·Yoshitomo ChiharaYoshihiko Hirao
Jul 13, 2005·Transfusion Medicine Reviews·Mark H Yazer
Sep 9, 2005·Cancer·Shuya HiraoKarl T Kelsey
Jan 31, 2006·European Urology·Richard J SylvesterKarlheinz Kurth
Mar 15, 2006·Oncogene·D LindgrenM Höglund
May 10, 2008·PLoS Genetics·David MelzerLuigi Ferrucci
Apr 16, 2009·Epidemiology·Marcel WolbersEwout W Steyerberg
Sep 18, 2009·The Journal of Urology·Jesus Fernandez-GomezJose Antonio Martinez-Piñeiro
May 31, 2011·European Urology·Jesus Fernandez-GomezUNKNOWN Club Urológico Español de Tratamiento Oncológico
Jul 27, 2011·The Journal of Urology·Harry W Herr
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jun 14, 2013·Urology·Tianyuan XuZhoujun Shen
Jul 6, 2013·European Urology·Marko BabjukUNKNOWN European Association of Urology
Citations
Mar 29, 2014·International Urology and Nephrology·Evren SüerYaşar Bedük
Mar 19, 2015·World Journal of Urology·Oliver EngelMichael Rink
Oct 1, 2015·BMC Surgery·Wei WangMinxin Shi
Oct 14, 2016·Chinese Journal of Cancer·Ting JinWei-Han Hu
Jan 13, 2018·Frontiers in Surgery·Su Jung OhThomas Steuber
Aug 19, 2015·Korean journal of urology·M Hammad Ather, Syed M Nazim
Feb 1, 2018·Medicine·Shuao XiaoHongwei Zhang
Mar 17, 2020·Internal Medicine·Yoshinori TanakaUNKNOWN Ehime Pancreato-Cholangiology (EPOCH) Study Group
Jul 24, 2020·PloS One·Monica S Y NgAndrew J Mallett
Apr 21, 2018·BMC Cancer·Veronika SeebacherNicole Concin
Aug 1, 2018·Oncology Letters·Donatas StakišaitisVita Lesauskaitė